Isofol Medical AB (publ) publishes interim report, January–March 2022
GOTHENBURG, Sweden, May 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report […]
Regulatory
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021
GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report
Notice to attend the Annual General Meeting held on May 19, 2022 in Isofol Medical AB (publ)
GOTHENBURG, Sweden, April 12, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical
Isofol Medical AB’s (publ) Nomination Committee proposes New Chair of the Board
GOTHENBURG, Sweden, April 8, 2022 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), proposes that Jan
Isofol Medical AB (publ) publishes year-end report, January – December 2021
GOTHENBURG, Sweden, February 24, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report
Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision
GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and
Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)
GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and
Isofol appoints nomination committee ahead of the Annual General Meeting 2022
GOTHENBURG, Sweden, November 19, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol Medical AB (publ) publishes interim report for January – September 2021
GOTHENBURG, Sweden, November 11, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm
GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the